Nomogram-based Prediction of Overall Survival in Patients with Metastatic Urothelial Carcinoma Receiving First-line Platinum-based Chemotherapy: Retrospective International Study of Invasive/Advanced Cancer of the Urothelium (RISC)

European Urology

Volumn 71, Issue 2, 2017, Pages 281-289

  Necchi, Andrea ^a   Sonpavde, Guru ^b   Lo Vullo, Salvatore ^a   Giardiello, Daniele ^a   Bamias, Aristotelis ^c   Crabb, Simon J ^d   Harshman, Lauren C ^e   Bellmunt, Joaquim ^e   De Giorgi, Ugo ^f   Sternberg, Cora N ^g   Cerbone, Linda ^g   Ladoire, Sylvain ^h   Wong, Yu Ning ⁱ   Yu, Evan Y ^j   Chowdhury, Simon ^k   Niegisch, Gunter ^l   Srinivas, Sandy ^m   Vaishampayan, Ulka N ⁿ   Pal, Sumanta K ^o   Agarwal, Neeraj ^p   Alva, Ajjai ^q   Baniel, Jack ^r   Golshayan, Ali Reza ^s   Morales Barrera, Rafael ^t   Bowles, Daniel W ^u   Milowsky, Matthew I ^v   Theodore, Christine ^w   Berthold, Dominik R ^x   Daugaard, Gedske ^y   Sridhar, Srikala S ^z   Powles, Thomas ^aa   Rosenberg, Jonathan E ^ab   Galsky, Matthew D ^ac   Mariani, Luigi ^a   more..

^a NATIONAL CANCER INSTITUTE   (Italy)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^c UNIVERSITY OF ATHENS   (Greece)

^d UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^e DANA FARBER CANCER INSTITUTE   (United States)

^f DEPARTMENT OF MEDICAL ONCOLOGY   (Italy)

^g SAN CAMILLO FORLANINI HOSPITAL   (Italy)

^h CENTRE GEORGES FRANÇOIS LECLERC   (France)

ⁱ FOX CHASE CANCER CENTER   (United States)

^j UNIVERSITY OF WASHINGTON   (United States)

^k GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

^l Department of Orthopedic Surgery   (Germany)

^m STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

ⁿ KARMANOS CANCER INSTITUTE   (United States)

^o CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^p UNIVERSITY OF UTAH   (United States)

^q UNIVERSITY OF MICHIGAN   (United States)

^r RABIN MEDICAL CENTER   (Israel)

^s MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^t VALL D HEBRON UNIVERSITY HOSPITAL   (Spain)

^u VETERANS AFFAIRS MEDICAL CENTER   (United States)

^v UNIVERSITY OF NORTH CAROLINA   (United States)

^w FOCH HOSPITAL   (France)

^x LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^y University of Copenhagen   (Denmark)

^z UNIVERSITY HEALTH NETWORK   (Canada)

^aa QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^ab MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^ac MOUNT SINAI SCHOOL OF MEDICINE   (United States)

more..

Author keywords

Nomogram; Overall survival; Platinum chemotherapy; Prognosis; Urothelial carcinoma

Indexed keywords

ANTINEOPLASTIC METAL COMPLEX; CARBOPLATIN; CISPLATIN; GEMCITABINE; TAXANE DERIVATIVE; ANTINEOPLASTIC AGENT;

ADULT; AGED; ARTICLE; BODY MASS; BONE METASTASIS; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER PROGNOSIS; CANCER SURVIVAL; COMORBIDITY; CONTROLLED STUDY; ETHNICITY; FEMALE; FOLLOW UP; HUMAN; LEUKOCYTE COUNT; LIVER METASTASIS; LUNG METASTASIS; MAJOR CLINICAL STUDY; MALE; NOMOGRAM; OVERALL SURVIVAL; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SURVIVAL PREDICTION; TRANSITIONAL CELL CARCINOMA; INTERNATIONAL COOPERATION; MIDDLE AGED; MORTALITY; PATHOLOGY; PROGNOSIS; RANDOMIZATION; SECONDARY; SURVIVAL ANALYSIS; URINARY TRACT TUMOR; VALIDATION STUDY;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, TRANSITIONAL CELL; CISPLATIN; FEMALE; HUMANS; INTERNATIONALITY; MALE; MIDDLE AGED; NOMOGRAMS; PROGNOSIS; RANDOM ALLOCATION; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; UROLOGIC NEOPLASMS;

EID: 84992183907     PISSN: 03022838     EISSN: 18737560     Source Type: Journal    
DOI: 10.1016/j.eururo.2016.09.042     Document Type: Article

References (20)

1. [1] Sonpavde, G., Jones, B.S., Bellmunt, J., Choueiri, T.K., Sternberg, C.N., Future directions and targeted therapies in bladder cancer. Hematol Oncol Clin North Am 29 (2015), 361–376.
2. [2] Powles, T., Eder, J.P., Fine, G.D., et al. MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature 515 (2014), 558–562.
3. [3] Rosenberg, J.E., Hoffman-Censits, J., Powles, T., et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicenter, phase 2 trial. Lancet 387 (2016), 1909–1920.
4. [4] Plimack, E.R., Bellmunt, J., Gupta, S., et al. Pembrolizumab (MK-3475) for advanced urothelial cancer: updated results and biomarker analysis from KEYNOTE-012. J Clin Oncol, 33, 2015 abstr 4502.
5. [5] Abida, W., Bajorin, D.F., Rosenberg, J.E., First-line treatment and prognostic factors of metastatic bladder cancer for platinum-eligible patients. Hematol Oncol Clin North Am 29 (2015), 319–328.
6. [6] Bajorin, D.F., Dodd, P.M., Mazumdar, M., et al. Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy. J Clin Oncol 17 (1999), 3173–3181.
7. [7] Apolo, A.B., Ostrovnaya, I., Halabi, S., et al. Prognostic model for predicting survival of patients with metastatic urothelial cancer treated with cisplatin-based chemotherapy. J Natl Cancer Inst 105 (2013), 499–503.
8. [8] Galsky, M.D., Moshier, E., Krege, S., et al. Nomogram for predicting survival in patients with unresectable and/or metastatic urothelial cancer who are treated with cisplatin-based chemotherapy. Cancer 11 (2013), 3012–3019.
9. [9] Sonpavde, G., Watson, D., Tourtellot, M., et al. Administration of cisplatin-based chemotherapy for advanced urothelial carcinoma in the community. Clin Genitourin Cancer 10 (2012), 1–5.
10. [10] Galsky, M.D., Chen, G.J., Oh, W.K., et al. Comparative effectiveness of cisplatin-based and carboplatin-based chemotherapy for treatment of advanced urothelial carcinoma. Ann Oncol 23 (2012), 406–410.
11. [11] Sonpavde, G., Galsky, M.D., Vogelzang, N.J., First-line systemic therapy trials for advanced transitional-cell carcinoma of the urothelium: should we stop separating cisplatin-eligible and -ineligible patients?. J Clin Oncol 28 (2010), e441–e442.
12. [12] Galsky, M.D., Moshier, E., Krege, S., et al. Post-treatment prognostic nomogram for patients with metastatic urothelial cancer completing first-line cisplatin-based chemotherapy. Urol Oncol, 32, 2014, 48 e1-8.
13. [13] Schemper, M., Smith, T.L., A note on quantifying follow-up in studies of failure time. Control Clin Trials 17 (1996), 343–346.
14. [14] Hastie, T., Tibshirani, R., Friedman, J., et al. The elements of statistical learning. 2nd ed., 2009, Springer Inc., New York, NY.
15. [15] Harrell, F.E. Jr., Lee, K.L., Mark, D.B., Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med 15 (1996), 361–387.
16. [16] Crowson, C.S., Atkinson, E.J., Therneau, T.M., Assessing calibration of prognostic risk scores. Stat Methods Med Res 25 (2016), 1692–1706.
17. [17] Schemper, M., Henderson, R., Predictive accuracy and explained variation in Cox regression. Biometrics 56 (2000), 249–255.
18. [18] Vickers, A.J., Elkin, E.B., Decision curve analysis: a novel method for evaluating prediction models. Med Decis Making 26 (2006), 565–574.
19. [19] Nguyen, C.T., Kattan, M.W., How to tell if a new marker improves prediction. Eur Urol 60 (2011), 226–228.
20. [20] Locke, J.A., Pond, G.R., Sonpavde, G., et al. Cisplatin- versus non-cisplatin-based first-line chemotherapy for advanced urothelial carcinoma previously treated with perioperative cisplatin. Clin Genitourin Cancer 14 (2016), 331–340.